ALT vs UNH

Altimmune continues to demonstrate significant 10x growth potential, primarily driven by Pemvidutide, its differentiated dual GLP-1/glucagon agonist. The recent FDA Breakthrough Therapy Designation for MASH is a pivotal, highly positive development, substantially de-risking the program and accelerating its path to market leadership in a multi-billion dollar TAM. A bolstered cash position of $340M ...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...